[{"orgOrder":0,"company":"Spaulding Clinical, LLC","sponsor":"Theriva Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"SYN-020","moa":"Intestinal alkaline phosphatase","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Spaulding Clinical, LLC","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule, Delayed Release","sponsorNew":"Spaulding Clinical, LLC \/ Spaulding Clinical, LLC","highestDevelopmentStatusID":"6","companyTruncated":"Spaulding Clinical, LLC \/ Spaulding Clinical, LLC"},{"orgOrder":0,"company":"Spaulding Clinical, LLC","sponsor":"Theriva Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"SYN-020","moa":"Intestinal alkaline phosphatase","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Spaulding Clinical, LLC","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule, Delayed Release","sponsorNew":"Spaulding Clinical, LLC \/ Spaulding Clinical, LLC","highestDevelopmentStatusID":"6","companyTruncated":"Spaulding Clinical, LLC \/ Spaulding Clinical, LLC"},{"orgOrder":0,"company":"Spaulding Clinical, LLC","sponsor":"Raziel Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"ISRAEL","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"RZL-012","moa":"Lipolysis","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Spaulding Clinical, LLC","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Spaulding Clinical, LLC \/ Spaulding Clinical, LLC","highestDevelopmentStatusID":"8","companyTruncated":"Spaulding Clinical, LLC \/ Spaulding Clinical, LLC"},{"orgOrder":0,"company":"Spaulding Clinical, LLC","sponsor":"Aptinyx","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"NYX-2925","moa":"N-methyl-D-aspartate receptor (NMDAR)","graph1":"Undisclosed","graph2":"Phase I","graph3":"Spaulding Clinical, LLC","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Spaulding Clinical, LLC \/ Spaulding Clinical, LLC","highestDevelopmentStatusID":"6","companyTruncated":"Spaulding Clinical, LLC \/ Spaulding Clinical, LLC"},{"orgOrder":0,"company":"Spaulding Clinical, LLC","sponsor":"Novan","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Berdazimer Sodium","moa":"polymers||Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Spaulding Clinical, LLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Spaulding Clinical, LLC \/ Spaulding Clinical, LLC","highestDevelopmentStatusID":"10","companyTruncated":"Spaulding Clinical, LLC \/ Spaulding Clinical, LLC"},{"orgOrder":0,"company":"Spaulding Clinical, LLC","sponsor":"Royal DSM","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"NETHERLANDS","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Bemotrizinol","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase III","graph3":"Spaulding Clinical, LLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Spaulding Clinical, LLC \/ Spaulding Clinical, LLC","highestDevelopmentStatusID":"10","companyTruncated":"Spaulding Clinical, LLC \/ Spaulding Clinical, LLC"}]

Find Clinical Drug Pipeline Developments & Deals by Spaulding Clinical, LLC

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          ISPE Annual Meeting
                          Not Confirmed
                          ISPE Annual Meeting
                          Not Confirmed

                          Details : SYN-020 is a Enzyme drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Radiation Enteritis.

                          Product Name : Undisclosed

                          Product Type : Enzyme

                          Upfront Cash : Inapplicable

                          September 16, 2021

                          Lead Product(s) : SYN-020

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase I

                          Recipient : Theriva Biologics

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          ISPE Annual Meeting
                          Not Confirmed
                          ISPE Annual Meeting
                          Not Confirmed

                          Details : SYN-020 is a Enzyme drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Radiation Enteritis.

                          Product Name : Undisclosed

                          Product Type : Enzyme

                          Upfront Cash : Inapplicable

                          March 25, 2021

                          Lead Product(s) : SYN-020

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase I

                          Recipient : Theriva Biologics

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          ISPE Annual Meeting
                          Not Confirmed
                          ISPE Annual Meeting
                          Not Confirmed

                          Details : Bemotrizinol is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          April 21, 2020

                          Lead Product(s) : Bemotrizinol

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Recipient : Royal DSM

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          ISPE Annual Meeting
                          Not Confirmed
                          ISPE Annual Meeting
                          Not Confirmed

                          Details : RZL-012 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Obesity.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          May 31, 2017

                          Lead Product(s) : RZL-012

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : Phase II

                          Recipient : Raziel Therapeutics

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          ISPE Annual Meeting
                          Not Confirmed
                          ISPE Annual Meeting
                          Not Confirmed

                          Details : NYX-2925 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          July 15, 2016

                          Lead Product(s) : NYX-2925

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Recipient : Aptinyx

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          ISPE Annual Meeting
                          Not Confirmed
                          ISPE Annual Meeting
                          Not Confirmed

                          Details : SB204 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Acne Vulgaris.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          October 20, 2015

                          Lead Product(s) : Berdazimer Sodium

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase I

                          Recipient : Novan

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank